Sugi Predict

Sugi Predict / Compounds / SCHEMBL17845927

SCHEMBL17845927

SCHEMBL17845927

Brc1ccc2ncnc(NCc3ccccc3)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 8/20 1.00
▸ HTT P42858 7/20 1.00
▸ SMN1; SMN2 Q16637 3/20 1.00
▸ RXFP1 Q9HBX9 1/20 0.74
▸ EGFR P00533 8/20 0.72
▸ GALR3 O60755 2/20 0.70
▸ NR2F2 P24468 2/20 0.70
▸ RAB9A P51151 1/20 0.70
▸ MAPK1 P28482 4/20 0.68
▸ TSHR P16473 3/20 0.68
▸ ALDH1A1 P00352 5/20 0.64
▸ HPGD P15428 4/20 0.64
▸ NOD2 Q9HC29 1/20 0.64
▸ CYP1A2 P05177 3/20 0.62
▸ CYP3A4 P08684 3/20 0.62
▸ CYP2D6 P10635 3/20 0.62
▸ HSD17B10 Q99714 3/20 0.62
▸ KDM4E B2RXH2 3/20 0.62
▸ USP2 O75604 2/20 0.62
▸ CLK4 Q9HAZ1 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9921343 0.91 HTT (0.83) LMNAHTTSMN1; SMN2RXFP1EGFR
SCHEMBL13170948 0.86 HTT (0.75) LMNAHTTSMN1; SMN2RXFP1EGFR
SCHEMBL13283269 0.86 HTT (0.76) LMNAHTTSMN1; SMN2RXFP1EGFR
SCHEMBL11887799 0.85 HTT (1.00) LMNAHTTSMN1; SMN2RXFP1EGFR
SCHEMBL18895168 0.85 HTT (0.74) LMNAHTTSMN1; SMN2RXFP1EGFR
SCHEMBL9921364 0.84 LMNA (0.72) LMNAHTTSMN1; SMN2EGFRGALR3
SCHEMBL1734678 0.84 LMNA (0.72) LMNAHTTSMN1; SMN2EGFRGALR3
SCHEMBL29386010 0.83 EGFR (1.00) LMNAHTTSMN1; SMN2EGFRGALR3
SCHEMBL7612718 0.83 EGFR (1.00) LMNAHTTSMN1; SMN2EGFRGALR3
Hydrochloric Acid SCHEMBL8178476 0.81 LMNA (1.00) LMNAHTTSMN1; SMN2EGFRGALR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11607414-B2 Small molecule inhibitors of EGFR and PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-03-21 — — US disclosed
EP-3233085-B1 QUINAZOLINE COMPOUNDS AS INHIBITORS OF EGFR AND PI3K UNIV MICHIGAN REGENTS (US) 2022-09-07 — — EP disclosed
US-20220202818-A1 COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-06-30 — — US disclosed
EP-3955923-A1 COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER The Regents Of The University Of Michigan (US) 2022-02-23 — — EP disclosed
CN-113354617-A Small molecule inhibitors of EGFR and PI3K 密歇根大学董事会 2021-09-07 — — CN disclosed
CN-107531665-B Small molecule inhibitors of EGFR and PI3K 密歇根大学董事会 2021-03-30 — — CN disclosed
US-20210023085-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2021-01-28 — — US disclosed
US-10842791-B2 Small molecule inhibitors of EGFR and PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-11-24 — — US disclosed
WO-2020215037-A1 COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-10-22 — — WO disclosed
US-20190167686-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2019-06-06 — — US disclosed
US-10206924-B2 Small molecule inhibitors of EGFR and PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2019-02-19 — — US disclosed
US-20170360788-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-12-21 — — US disclosed
EP-3233085-A2 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K The Regents of The University of Michigan (US) 2017-10-25 — — EP disclosed
WO-2016100347-A2 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10206924-B2 Small molecule inhibitors of EGFR and PI3K EGFR, ERBB2, ERBB3 LMNA 4781/4885HTT 2296/4885SMN1; SMN2 4865/4885
US-20170360788-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K EGFR, ERBB2, ERBB3 LMNA 4781/4885HTT 2296/4885SMN1; SMN2 4865/4885
US-11607414-B2 Small molecule inhibitors of EGFR and PI3K EGFR, ERBB2, ERBB3 LMNA 4781/4885HTT 2296/4885SMN1; SMN2 4865/4885
US-20210023085-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K EGFR, ERBB2, ERBB3 LMNA 4781/4885HTT 2296/4885SMN1; SMN2 4865/4885
US-10842791-B2 Small molecule inhibitors of EGFR and PI3K EGFR, ERBB2, ERBB3 LMNA 4781/4885HTT 2296/4885SMN1; SMN2 4865/4885
US-20190167686-A1 SMALL MOLECULE INHIBITORS OF EGFR AND PI3K EGFR, ERBB2, ERBB3 LMNA 4781/4885HTT 2296/4885SMN1; SMN2 4865/4885
US-20220202818-A1 COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER CD274, PDCD1, PDCD1LG2 LMNA 4139/4885HTT 4472/4885SMN1; SMN2 2483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.